Premarin
Product Images NDC 43353-687

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Premarin (NDC 43353-687). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 0.3mg (43353 687)

Label for Premarin 0.3 mg tablets, containing 90 tablets. The label lists the manufacturer as Wyeth Laboratories Inc., Philadelphia, PA, and indicates repackaging by Aphena Pharma Solutions - Tennessee, Inc. It includes storage instructions for controlled room temperature and warnings about dispensing in a light-resistant container with child safety in mind. The label features barcodes and a National Drug Code (NDC) number 43353-0687-60.*

FDA Label Image

Bottle Label 0.625mg (43353 688)

Premarin 0.625 mg tablet bottle label showing 90 tablets. The label includes storage instructions to keep between 20-25°C and to dispense in a light-resistant container. It notes manufacturing by Wyeth Laboratories Inc., Philadelphia, PA, and repackaging by Aphena Pharma Solutions - Tennessee, Inc. Batch, expiration, and lot number fields are present but not filled in.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Computer_8.jpg (Computer)

FDA Label Image

Phone_5.jpg (Phone)

Premarin tablet blister packaging prominently showing the brand name 'PREMARIN' and a grid of tablets arranged in a foil blister pack. The packaging is white with a mix of dark and light rectangular blocks visually outlining the arrangement of tablets. Labeler Aphena Pharma Solutions - Tennessee, Inc. is indicated in the product data but not visible in the image.*

FDA Label Image

Figure 1 (Premarin Tablets 01)

A cumulative percentage plot showing the percent change from baseline in spine bone mineral density (BMD) among subjects. The graph compares data for Premarin at doses 0.625, 0.45, and 0.3 along with a placebo group, with the X-axis representing percent change and the Y-axis representing cumulative percent of subjects.*

FDA Label Image

Figure 2 (Premarin Tablets 02)

A line graph depicting the adjusted percent change from baseline over multiple cycles for different dosage groups (0.625, 0.45, 0.3) and placebo, as part of data related to the drug Premarin. The x-axis represents the cycle number, and the y-axis shows the adjusted percent change from baseline with error bars indicating variability.*

FDA Label Image

Pfizer-logo (Premarin Tablets 03)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.